* 200040 2011 ADDF/AHA HCM HCM HCM HCM R542.2 A1672-9188 2013 04-0235-06 235 Diagnosis and treatment of hypertrophic cardiomyopathy based on the guideline ZHANG Yan, WANG Jun*, WANG Ming-he Department of Cardiology, Huashan Hospital, Fudan University Jing an Branch, Shanghai 200040, China Abstract: 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy HCM provides a reference for the diagnosis and treatment of HCM, to which clinicians should pay more attention. This review interprets the diagnostic technology and treatment methods of HCM as a highlight of the new guideline. Key words: hypertrophic cardiomyopathy; disease gene; diagnosis; treatment HCM 0.2% 0.5% 1 1% 2 HCM 0.16% 100 HCM 3 1/4 HCM HCM SCD 1 HCM 2012-12-28 2013-01-27 2/3 HCM 4-5 HCM 900 β MYH7 C MYBPC3 T TNT 13 6 MYH7 MYBPC3 TNT 3 HCM 3/4 2 MYBPC3 HCM 7 HCM 8 HCM HCM
236 HCM 2 HCM LVOT 9 HCM 6 2.1 LVOT HCM 10 HCM 1/3 30 mmhg 1/3 HCM 30 mmhg 30 mmhg 11 1/3 HCM 30 mmhg 50 mmhg LVOT Venturi SAM LVOT LVOT LVOT 12 2.2 LVOT 9 HCM 13 HCM LOVT SAM LVOT 3 3.1 HCM NYHA 14 - LVOT HCM SCD 35% SCD 15 16 AF
3.2 HCM 75% 95% 12 ECG 17 ST T Q ECG T V3 V5 ST-T AHCM ECG HCM 24 AF NSVT SCD HCM NYHA 3.3 HCM 2011 / ACCF/AHA HCM 9 TTE HCM HCM HCM 12 18 18 TEE HCM 15 mm 19 30 mm SCD HCM 1.3 1.5 =1.03±0.07 3.4 CMR CMR HCM Maron 20-21 CMR 6% HCM AHCM HCM 3.5 CT HCM CHD HCM HCM CHD CHD HCM HCM HCM 40 HCM CT 3.6 HCM HCM HCM 22 HCM 4 HCM SCD 237
238 SCD 12 10% SCD 2 SCD 6 SCD NSVT Monserrat 23 NSVT SCD 30 30 mm SCD 20 mmhg 20 mmhg 10% 20% 85% 95% 3% 5 5.1 2 HCM SCD SCD LVH LVH 12 21 1 5 2, 9 5.2 HCM LVOT HCM 9 60 65 /min 9 CCB 480 mg 9 CCB HOCM 24 HOCM CCB a 9 100 200 mg 3 HOCM 5.3 DDD LVOT 30 mmhg 50 mmhg DDD DDD LVOT Megevand 25 18 DDD 4.1 10 50% 44% 17% 28% P 0.05 2.4 NYHA
1.8 P=0.02 LVOT 82± 35 mmhg 32±23 mmhg P 0.001 5.4 ICD 2011 ACCF/AHA HCM HCM ICD B 1 ICD a 9 SCD ICD HCM 5.5 HOCM 26 HCM LVOT 50 mmhg Mcleod 27 Mayo Clinic 125 ICD ICD LVOT HCM 5.6 PTSMA PTSMA HOCM PTSMA MCE PTSMA HOCM 15 mm / / LVOT LVOTG 50 mmhg 30 50 mmhg 70 mmhg PTSMA Brown 28 2 959 HCM 12 LVOT 65 mmhg 16 mmhg P 0.001 21 mm 14 mm P 0.001 PTSMA HCM PTSMA 5% 30% 1 Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Com ittee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary W orking Groups; and Coun cil on Epidemiology and Prevention J. Circulation, 2006, 113 14 : 1807-1816. 2 Ho CY. Hypertrophic cardiomyopathy in 2012 J. Circulation, 2012, 125 11 : 1432-1438. 3 Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults J. Am J Med, 2004, 116 1 : 14-18. 4 Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy J. J Mol Cell Cardiol, 2001, 33 4 : 655-670. 5,,,. DNA J., 1998, 38 7 : 3-4. 6 Geisterfer-Lowrance AAT, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a p cardiac myosin heavy chain gene missense mutation J. Cell, 1990, 62 5 : 999-1006 7 Oliva-Sandoval MJ, Ruiz-Espejo F, Monserrat L, et al. 239
240 Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 1 8 Spanish families with a single mutation in MYBPC3 J. Heart, 2010, 96 24 : 1980-1984. 8 Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy J. Mayo Clin Proc, 2003, 83 6 : 630-638. 9 Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Circulation, 2011, 124 24 : e783-e831. 10 Elliott PM, Gimeno JR, Tomé MT, et al. J., 2007, 3 1 : 51-52. 11 Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction J. Circulation, 2006, 114 21 : 2232-2239. 12 Geske JB, Sorajja P, Ommen SR, et al. Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy J. Clin Cardiol, 2009, 32 7 : 397-402. 13 Maron MS, Olivotto I, Maron BJ, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy J. J Am Coll Cardiol, 2009, 54 9 : 866-875. 14,,. J., 2007, 35 1 : 5-16. 15 Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy J. Circulation, 2010, 121 3 : 445-456. 16 Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy J. Circulation, 2006, 114 3 : 216-225. 17 Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J. J Am Coll Cardiol, 2003, 42 9 : 1687-1713. 18 Sorajja P, Nishimura RA, Gersh BJ, et al. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study J. J Am Coll Cardiol, 2009, 54 3 : 234-241. 19 Maron BJ, Casey SA, Hurrell DG, et al. Relation of left ventricular thickness to age and gender in hypertrophic cardiomyopathy J. Am J Cardiol, 2003, 91 10 : 1195-1198. 20 Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance J. J Am Coll Cardiol, 2009, 54 3 : 220-228. 21 Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy J. Circulation, 2008, 118 15 : 1541-1549. 22 Christiaans I, van Langen IM, Birnie E, et al. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study J. Am J Med Genet A, 200, 149A: 602-612. 23 Monserrat L, Elliott PM, Gimeno JR. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients J. J Am Coll Cardiol, 2003, 42 5 : 873-879. 24 Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy J. Circulation, 2008, 117 3 : 429-439. 25 Megevand A, Ingles J, Richmond DR, et al. Long term follow up of patients with obstructive hypertrophic cardiomyopathy treated with dual chamber pacing J. Am J Cardiol, 2005, 95 8 : 991-993. 26 Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy J. J Am Coll Cardiol, 2005, 46 3 : 470-476. 27 Mcleod CJ, Ommen SR, Ackerman MJ, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy J. Eur Heart J, 2007, 28 21 : 2583-2588. 28 Brown ML, Schaff HV. Surgical management of hypertrophic cardiomyopathy in 2007: what is new? J. World J Surg, 2008, 32 3 : 350-354.